Incyte Aktie News

MORGES, Switzerland--(BUSINESS WIRE)---- $INCY--Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC).

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) announced today that it has scheduled its fourth quarter and year-end 2025 financial results conference call and webcast for 8:00 a.m. ET on Tuesday, February 10, 2026. The schedule for the press release and conference call/webcast is as follows: Q4 & YE 2025 Press Release: February 10, 2026 at 7:00 a.m. ET Q4 & YE 2025 Conference Call: Fe...

Incyte offers a compelling risk-adjusted return profile, outperforming healthcare benchmarks with robust growth and moderate volatility. INCY is successfully transitioning from Jakafi dependence to a diversified Hematology/Oncology, Immunology, and Autoimmunity portfolio, driving double-digit revenue growth. Third-quarter 2025 revenue rose 20% YoY to $1.37B, and operating income was up 204%.

Incyte Corporation earns a Strong Buy rating, with recent execution driving a 56% stock rally and robust revenue growth. Jakafi sales rose 6.7% YoY in Q3 2025, defying terminal decline fears, while ex-Jakafi business surged 45% YoY. Management projects ex-Jakafi revenues to triple by 2030, with pipeline catalysts and Jakafi XR mitigating the 2028 patent cliff.

Incyte is a rare, profitable biotech with earnings doubling since 2021, driven by its core hematology franchise and rapidly expanding dermatology and oncology portfolios. INCY's non-Jakafi portfolio is rapidly expanding, with Opzelura and oncology assets driving double-digit growth and significant margin improvement. Management targets 15–20% five-year sales CAGR and $3–4B ex-Jakafi revenue by ...

Micron Technology (MU) leads Steven Cress' Top 10 Stocks for 2026, driven by sector-leading growth, profitability, and a compelling valuation despite a 254% 1-year return. AI remains a central investment theme, with hyperscalers like MU, AMD, and CIEN benefiting from robust CapEx, strong forward EPS growth, and discounted PEG ratios.

Incyte Corporation (INCY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Medicine remains one of the most potentially rewarding of all investment areas. And this biotech stock is flirting with a buy point as analysts see earnings skyrocketing.